Plasmonic Substrates are the basis for
High-Sensitivity Fluorescence-Immunoassays
(∗ developed with Blu-Ray Technologie in Cooperation with Sony DADC Biosciences GMBH, now STRATEC Consumables GMBH )
FIANOSTICS welcomes

Josef Schabauer
Our new Partner
After studying Natural Sciences at the University of Natural Resources and Applied Life Sciences Vienna, Josef started his professional career at Unilever. In 1989, he joined Abbott, a global leader in the healthcare industry. Josef held several leading management positions at Abbott: Commercial Manager Abbott Diagnostics Austria, Customer Experience Director of the DACH- and BeNeLux region, Managing Director of Abbott Diagnostics Switzerland and CEO/County Manager Abbott Austria GesmbH, among others.
In the beginning of 2020, Josef became partner at FIANOSTICS. He will use his significant industry expertise in vitro diagnostics as well as his long-lasting networks to drive our strategic commercialization efforts. Wiener Neustadt, June 2020
In the beginning of 2020, Josef became partner at FIANOSTICS. He will use his significant industry expertise in vitro diagnostics as well as his long-lasting networks to drive our strategic commercialization efforts. Wiener Neustadt, June 2020
FIANOSTICS is very happy that Josef has joined our team. We are very much looking forward to a successful cooperation. Dr. Gerhard Hawa Founder / CEO
Our Timeline
2015Foundation
Formation of Fianostics GmbH2017First Product
FluoBolt™-NOGGIN
MEF-FIA for the quantitative determination of NOGGIN in serum and plasma2018Second Product
FluoBolt™-ASPORIN
This protein plays an important role in osteoarthritis, lumbar disc damage and tumor progression2018ISO 13485:2016
FIANOSTICS obtains certification for ISO 13485:2016 Medical devices - Quality management systems - Requirements for regulatory purposes- As of now our products are available with CE marking
2018Third Product
FluoBolt™-PERIOSTIN
assay is your high-sensitivity alternative to conventional PERIOSTIN-ELISA kits2019Fourth Product
FluoBolt™-KLOTHO
We decided to use our FluoBolt™-Technology to provide a high sensitivity α-KLOTHO assay for clinical research, that may improve data consistency2020Fifth Product
FluoBolt™-WNT3A
2021Sixth Product
Cov19 FluoBoltTM-DAT
2022Further Products
New Biomarkers with high clinical potential to bone metabolism- and neurodegenerative disorders